Incyte Corporation

NasdaqGS:INCY Stock Report

Market Cap: US$12.9b

Incyte Future Growth

Future criteria checks 4/6

Incyte is forecast to grow earnings and revenue by 46.9% and 8.9% per annum respectively. EPS is expected to grow by 46.7% per annum. Return on equity is forecast to be 24.5% in 3 years.

Key information

46.9%

Earnings growth rate

46.7%

EPS growth rate

Biotechs earnings growth27.5%
Revenue growth rate8.9%
Future return on equity24.5%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Recent updates

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Oct 31

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06
It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

May 07
We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

May 03
Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Incyte: A Potential GARP Superstar

Feb 27

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Oct 07

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Sep 29

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

Earnings and Revenue Growth Forecasts

NasdaqGS:INCY - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265,1341,2641,5651,65119
12/31/20254,6429691,2671,16123
12/31/20244,1997819332623
9/30/20244,0763217102N/A
6/30/20243,85797-140-61N/A
3/31/20243,768745791821N/A
12/31/20233,696598449496N/A
9/30/20233,609425566632N/A
6/30/20233,513366698781N/A
3/31/20233,470324561649N/A
12/31/20223,395341892970N/A
9/30/20223,331876711802N/A
6/30/20223,320945665760N/A
3/31/20223,115933609759N/A
12/31/20212,986949568749N/A
9/30/20212,913535543741N/A
6/30/20212,721338450668N/A
3/31/20212,703478569765N/A
12/31/20202,667-296-312-125N/A
9/30/20202,457-335-266-100N/A
6/30/20202,388-191-108-12N/A
3/31/20202,229-376-227-128N/A
12/31/20192,159447633711N/A
9/30/20192,108405589663N/A
6/30/20192,006306476592N/A
3/31/20191,997253392471N/A
12/31/20181,882109263336N/A
9/30/20181,798-10990163N/A
6/30/20181,729-102N/A17N/A
3/31/20181,534-167N/A101N/A
12/31/20171,536-313N/A-93N/A
9/30/20171,419-155N/A91N/A
6/30/20171,306-154N/A133N/A
3/31/20171,226-107N/A34N/A
12/31/20161,106104N/A305N/A
9/30/20161,023151N/A280N/A
6/30/201694174N/A193N/A
3/31/201685849N/A189N/A
12/31/20157547N/A89N/A
9/30/2015634-86N/A61N/A
6/30/201564413N/A81N/A
3/31/2015581-33N/A53N/A
12/31/2014511-48N/A26N/A
9/30/2014485-54N/A-30N/A
6/30/2014372-136N/A-70N/A
3/31/2014374-101N/A-47N/A
12/31/2013355-83N/A9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INCY's forecast earnings growth (46.9% per year) is above the savings rate (2.6%).

Earnings vs Market: INCY's earnings (46.9% per year) are forecast to grow faster than the US market (15.2% per year).

High Growth Earnings: INCY's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: INCY's revenue (8.9% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: INCY's revenue (8.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: INCY's Return on Equity is forecast to be high in 3 years time (24.5%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 23:48
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Incyte Corporation is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Thomas RussoBaird
Ishan MajumdarBaptista Research